Patient-centric eClinical tech can boost trials: Jeeva Informatics

By Jenni Spinner

- Last updated on GMT

(chpua/iStock via Getty Images Plus)
(chpua/iStock via Getty Images Plus)

Related tags Informatics eclinical Clinical trials software Patient centricity Clinical trial diversity Patient recruitment

Leaders from the trial tech provider discuss how human-focused technology on eClinical platforms can tackle inefficiencies associated with traditional studies.

According to Harsha Rajasimha, CEO and founder of Jeeva Informatics, clinical trials often are plagued by significant inefficiencies, which delay the availability of new drugs and treatments. By contrast, up-to-date platform technologies that take a patient-centric approach lead to greater speed, efficiency, and cost-effectiveness.

About 85% of clinical trials centered around new therapies new drugs and medical devices experience delays, Rajasimha pointed out, with more than 90% held back for a month or longer. The financial cost to drug developers can be hundreds of thousands of dollars per day.

While this is bad news for the pharmaceutical industry, not to mention patients hoping for new treatments, it is also a wake-up call​,” Rajasimha said. “Today’s technology and near-universal digital accessibility, offer ways to significantly lessen delays—and possibly costs—in clinical trials​.”

On top of delays, Rajasimha, remarked, traditional approaches to trial structure and management tend to hamper patient diversity. Reasons he cited include:

  • Trials typically are run in a small number of a limited number of large metropolitan cities.
  • Study protocol logistics are less than ideal for the participants concerned with missing work and finding childcare.
  • Information about trials is lacking.

Rajasimha added that patient participants tend to be white, with some study populations skewing around 90% white. For example, he stated, while people of color have a statistically greater disposition toward pancreatic cancer, they frequently are underrepresented in clinical trials for oncological treatments.

Sharlene Brown, director of business development for Jeeva Informatics, said underrepresentation can be tied to the narrow pool from which clinical trial teams tend to draw their patients. She related a story of meeting a patient foundation leader who was tasked with explaining to veteran trial operators why a proposed site in Vermont (a state with a population that is more than 94% white) would be less than ideal for recruiting patients for a sickle-cell study (a disease that disproportionately impacts non-white people).

These and other recruitment challenges, Rajasimha said, are one of the most significant contributing factors to trial delays. He pointed to data that shows earlier this year approximately 1,000 organizations involved in medical research announced delays or disruption in their trials, citing either slow enrollment or complex data handling challenges.

Rajasimha said the above problems could be abated by the adoption of a cloud-based decentralized trial approach. According to Rajasimha, this technology enables multidirectional communication between study sites and patient participants.

For example, he said, if empowered by the proper “bring-your-own-device” (BYOD) eClinical platform, anyone with access to a cell phone, or a tablet, or a PC, could use it to interact with the study investigator teams by video, telemedicine, SMS, or email. He pointed out that this approach could enable sponsors to elevate diversity and enrollment, for example, by using social media platforms.

The COVID-19 pandemic has necessitated some of these advancements, Rajasimha said, with restrictions inhibiting the ability to travel to sites.

Whatever we do, we must not go back but forward,​” Rajasimha said. “For the clinical trial process to live up to its own expectations, we must go where the people are, and communicate with them—and they with us—in the most effective way possible​.”

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more